Biotech Values

[bladerunner1717]

McBio,

There is a trial at http://clinicaltrials.gov/ct2/show/NCT01649336?term=mek-162&rank=10 that has MEK-162 being tested in combination with paclitaxel. ARRY is the sponsor of the trial, according to the site. Since we know, or thought we knew, that NVS's strategy with MEK-162 was to test in combo with other targeted therapies, does this mean that ARRY is doing some testing on its own? Is that even possible under the terms of the agreement? I can't imagine that NVS would let that happen. Or does this mean that NVS is expanding the scope of its testing with MEK-162 to now test in combo with chemotherapeutics?


Bladerunner